SECOND AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 13th, 2020 • 9 Meters Biopharma, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 13th, 2020 Company Industry JurisdictionThis SECOND AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”) is entered into effective May 1, 2020 (the “2nd A&R Effective Date”) by and between Naia Rare Diseases, Inc., a Cayman Islands corporation with a principal office at 336 Bon Air Center, P.O. Box 341, Greenbrae, CA 94904 (“Naia”), and Amunix Pharmaceuticals, Inc., a Delaware corporation with a principal office at 500 Ellis Street, Mountain View, CA 94043 (“Amunix”), referred to collectively as the “Parties” and individually as the or a “Party.
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 13th, 2020 • 9 Meters Biopharma, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 13th, 2020 Company Industry JurisdictionThis AMENDED AND LICENSE AGREEMENT (this “Agreement”) is entered into effective May 1, 2020 (the “A&R Effective Date”) by and between Naia Rare Diseases, Inc., a Cayman Islands corporation with a principal office at 336 Bon Air Center, P.O. Box 341, Greenbrae, CA 94904 (“Naia”), and Amunix Pharmaceuticals, Inc., a Delaware corporation with a principal office at 500 Ellis Street, Mountain View, CA 94043 (“Amunix”), referred to collectively as the “Parties” and individually as the or a “Party”.